title: PET neuroreceptor imaging as predictor of severe cerebral ischemic insult.
abstract: Measurement of the adenosine A1 receptor (A1-R) with positron emission tomography (PET) using a newly developed positron ligand, [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine (MPDX). were performed in a cat middle cerebral artery (MCA) occlusion and reperfusion. Eighteen adult cats underwent PET measurement of; 1) cerebral blood flow (CBF). 2) A1-R, 3) central benzodiazepine receptor (BDZ-R) and 4) glucose metabolism with 15O labeled water, MPDX, 11C-flumazenil (FMZ) and 18F-fluorodeoxyglucose (FDG), respectively. The CBF, A1-R, BDZ-R and FDG uptake were serially measured after 60 min occlusion of MCA in this order. MPDX binding and FMZ binding, but not CBF and FDG uptake, were significantly reduced in the groups with severer ischemic insult than in the groups with no or milder insults. Of the two receptor ligands, the reduction rate of the MPDX binding to A1-Rs was larger in a group that caused fatal ischemic insult. The newly developed PET in vivo imaging technique using MPDX was suitable in evaluating the function of adenosine and A1-Rs in relation to cerebral ischemia.
authors.affiliation: Department of Neurosurgery, Tokyo Medical and Dental University, Japan. nariai.nsrg@tmd.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Nariai
authors.forename: Y
authors.initials: Y
authors.lastname: Shimada
authors.forename: K
authors.initials: K
authors.lastname: Ishiwata
authors.forename: T
authors.initials: T
authors.lastname: Nagaoka
authors.forename: J
authors.initials: J
authors.lastname: Shimada
authors.forename: T
authors.initials: T
authors.lastname: Kuroiwa
authors.forename: K I
authors.initials: KI
authors.lastname: Ono
authors.forename: K
authors.initials: K
authors.lastname: Hirakawa
authors.forename: M
authors.initials: M
authors.lastname: Senda
authors.forename: K
authors.initials: K
authors.lastname: Ohno
mesh_terms: D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D002545:Brain Ischemia / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology*; D002415:Cats; D002560:Cerebrovascular Circulation; D003287:Contrast Media / Q000378:metabolism; D005442:Flumazenil / Q000378:metabolism; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D008024:Ligands; D011379:Prognosis; D043682:Receptor, Adenosine A1 / Q000378:metabolism; D011963:Receptors, GABA-A / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000378:metabolism*; D012720:Severity of Illness Index; D014055:Tomography, Emission-Computed; D014970:Xanthines / Q000378:metabolism
chemical_list: C451639:1-methyl-8-dicyclopropylmethyl-1-methyl-3-propylxanthine; D003287:Contrast Media; D008024:Ligands; D043682:Receptor, Adenosine A1; D011963:Receptors, GABA-A; D014970:Xanthines; D019788:Fluorodeoxyglucose F18; D005442:Flumazenil